Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?

Area of Science:

• Pulmonology
• Genetics
• Pharmacology

Background:

• Severe alpha(1)-antitrypsin (AAT) deficiency is an inherited condition leading to early-onset emphysema in smokers.
• Emphysema results from a protease-antiprotease imbalance due to insufficient AAT levels, causing lung tissue damage.

Purpose of the Study:

• To evaluate the clinical effectiveness of AAT replacement therapy in managing emphysema progression in AAT-deficient patients.
• To establish criteria for reserving AAT replacement therapy for specific patient subgroups.

Main Methods:

• Review of existing studies, including randomized trials, nonrandomized studies, and retrospective analyses, on AAT replacement therapy.
• Analysis of computed tomography (CT) scan data and forced expiratory volume in 1 second (FEV(1)) decline to assess disease progression.

Main Results:

• Current evidence for AAT replacement therapy's clinical effectiveness in reducing emphysema progression is limited.
• Some studies suggest potential benefits in slowing disease progression, particularly with CT scan evidence or FEV(1) decline.
• A randomized placebo-controlled trial with CT scan as the primary outcome is recommended.

Conclusions:

• AAT replacement therapy is recommended for AAT-deficient patients with significant FEV(1) impairment who have quit smoking and show rapid FEV(1) decline despite optimal care.
• Screening for AAT deficiency is advised in patients with atypical chronic obstructive pulmonary disease and their family members.